SAHPRA Approval of Lenacapavir: A New Era in HIV Prevention in South Africa

Key Takeaways

The South African Health Products Regulatory Authority (SAHPRA) has registered lenacapavir, a novel long-acting injectable capsid inhibitor, for HIV prevention, marking a significant regulatory advancement for the continent. Approved on October 27, 2025, lenacapavir represents the first African authorization of this mechanism class and positions South Africa ahead of other regional regulators in adopting innovative HIV prevention technologies. Why it matters: The approval introduces a biannual injectable alternative to daily oral PrEP, potentially transforming adherence dynamics and infection prevention outcomes in a country where HIV remains a substantial public health burden.

Drug Overview

Lenacapavir is a first-in-class capsid inhibitor—a novel drug class targeting HIV-1 replication at multiple stages of the viral lifecycle. Unlike traditional nucleoside reverse transcriptase inhibitors (NRTIs) or integrase strand transfer inhibitors (INSTIs) used in oral PrEP formulations, lenacapavir's mechanism disrupts HIV-1 capsid assembly and uncoating, offering a mechanistically distinct approach to infectious diseases prevention.

The drug is formulated as a subcutaneous injection administered every six months, fundamentally reshaping the user experience compared to daily oral PrEP regimens such as tenofovir disoproxil fumarate/emtricitabine (Truvada) or tenofovir alafenamide/emtricitabine (Descovy). SAHPRA approved lenacapavir for HIV-1 prevention in HIV-negative adults and adolescents weighing at least 35 kilograms. The biannual administration schedule addresses a critical barrier to PrEP efficacy: medication adherence. Daily oral regimens require sustained user engagement, whereas long-acting injectables reduce the burden of daily pill-taking and associated stigma, particularly in high-incidence settings where privacy concerns may limit consistent oral medication use.

Clinical Insights

SAHPRA's approval of lenacapavir was based on comprehensive clinical trial data demonstrating efficacy and safety in preventing HIV-1 infection among HIV-negative populations. Pivotal clinical trials established robust protection against HIV-1 acquisition in adults and adolescents weighing at least 35 kg. The specific trial protocols, primary endpoint definitions, and quantitative efficacy data (such as hazard ratios, confidence intervals, or infection rate reductions) were not disclosed in the regulatory submission summary available to the public.

The safety profile supported regulatory authorization in the target population. No specific adverse event data, grade ≥3 toxicities, or contraindications were detailed in SAHPRA's public announcement. However, the approval demonstrates that the benefit-risk profile was deemed favorable for HIV prevention in both adult and adolescent populations, a determination that typically reflects acceptable tolerability during extended follow-up in clinical trials.

The long-acting injectable formulation's pharmacokinetic profile—characterized by sustained drug concentrations over six-month intervals—underpins its efficacy advantage. Compared with daily oral PrEP, which requires consistent adherence to maintain protective plasma concentrations, lenacapavir's depot formulation maintains therapeutic levels with minimal user-dependent variability, potentially translating to superior real-world effectiveness in diverse adherence contexts.

Regulatory Context

SAHPRA registered lenacapavir on October 27, 2025, following comprehensive evaluation of preclinical, clinical, and manufacturing data. South Africa's approval positions the nation as the third global regulator to authorize lenacapavir for HIV-1 prevention, following the FDA and EMA. The specific regulatory pathway—whether standard or accelerated review—and submission classification details were not disclosed in publicly available sources.

The approval timeline reflects SAHPRA's commitment to timely access to innovative HIV prevention technologies while maintaining rigorous safety and efficacy standards. As a member of the African Medicines Regulatory Harmonisation (AMRH) initiative, SAHPRA's authorization may facilitate subsequent registrations across other African regulatory agencies, potentially accelerating regional access to lenacapavir and establishing a precedent for long-acting HIV therapeutics on the continent.

Market Impact

Lenacapavir's SAHPRA approval introduces a transformative option within South Africa's HIV prevention landscape, which has historically relied on daily oral PrEP regimens. The introduction of a long-acting injectable alternative addresses critical adherence barriers and may expand PrEP uptake among populations facing challenges with daily medication adherence, including adolescents, individuals in resource-limited settings, and those navigating stigma-related barriers to consistent oral medication use.

Compared with existing daily oral PrEP options, lenacapavir's biannual administration schedule reduces pill burden, healthcare visit frequency, and stigma-related medication visibility. These attributes may enhance retention in HIV prevention programs and improve population-level coverage in high-incidence regions. While specific pricing and reimbursement terms have not been publicly announced, lenacapavir is anticipated to complement rather than replace existing oral PrEP options, fostering a more diversified prevention market.

South Africa's HIV prevention market encompasses multiple oral PrEP formulations, post-exposure prophylaxis (PEP) regimens, and behavioral interventions. The addition of lenacapavir expands clinical choice and allows healthcare providers to tailor prevention strategies to individual patient preferences, adherence capacity, and risk profiles. This diversification aligns with South Africa's national HIV prevention strategy, which emphasizes combination prevention approaches and equitable access to evidence-based interventions.

What to watch next: The real-world impact of lenacapavir on PrEP uptake, adherence rates, and new HIV infections in South Africa will be critical to assess over the next 12–24 months, potentially informing policy decisions and investment priorities across the African region.

Future Outlook

SAHPRA's approval of lenacapavir signals a strategic regulatory openness to long-acting HIV therapeutics and positions South Africa as a regional leader in innovative HIV care adoption. This decision may catalyze further investment in long-acting HIV prevention and treatment modalities across Africa, including combination therapies and integrated care models that leverage depot formulations for improved adherence and clinical outcomes.

Ongoing real-world data collection and pharmacovigilance will be essential to monitor lenacapavir's long-term safety profile, resistance emergence patterns, and effectiveness in diverse South African populations. Integration of lenacapavir into national HIV prevention guidelines and public health programs will require coordination between SAHPRA, the Department of Health, and implementing partners to ensure equitable access and optimal clinical utilization.

South Africa's regulatory leadership in approving lenacapavir may influence harmonization efforts within the African Medicines Regulatory Harmonisation (AMRH) framework and the African Medicines Agency (AMA), potentially accelerating access across the continent. Future label expansions or combination regimens involving lenacapavir may also emerge as clinical experience accumulates and regulatory agencies evaluate additional indications or patient populations.

Frequently Asked Questions

References

1. South African Health Products Regulatory Authority (SAHPRA). "SAHPRA registers lenacapavir." News and Updates. Accessed April 20, 2026. https://www.sahpra.org.za/news-and-updates/sahpra-registers-lenacapavir

References

1. SAHPRA. . Accessed 2026-04-20.